Compare CNMD & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNMD | PHAR |
|---|---|---|
| Founded | 1970 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.5M | 1.0B |
| IPO Year | 1995 | 2020 |
| Metric | CNMD | PHAR |
|---|---|---|
| Price | $49.72 | $11.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $46.25 | $38.33 |
| AVG Volume (30 Days) | ★ 734.0K | 7.7K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | $10.04 |
| Revenue Next Year | $5.48 | $2.51 |
| P/E Ratio | ★ $40.26 | $3,041.22 |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $31.44 | $9.62 |
| 52 Week High | $56.64 | $21.34 |
| Indicator | CNMD | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 35.79 |
| Support Level | $40.14 | $9.62 |
| Resistance Level | $53.66 | $17.89 |
| Average True Range (ATR) | 2.10 | 0.48 |
| MACD | 0.25 | -0.12 |
| Stochastic Oscillator | 63.63 | 31.75 |
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.